Last updated 2026-07-26
TL;DR
CJC-1295 is most often paired with ipamorelin because they act on separate receptors (GHRH receptor vs ghrelin/GHS-R), a combination with real pharmacological logic. But no published human trial has tested that exact combo for the outcomes people want (fat loss, muscle, longevity). The rationale is sound; the clinical proof is not there yet.
What does it mean to "stack" CJC-1295 with another peptide?
Stacking just means taking two or more compounds together on the theory that they'll do more combined than either does alone. With CJC-1295, that almost always means pairing a GHRH receptor agonist with a ghrelin receptor agonist (a "GHRP" or ghrelin mimetic like ipamorelin, GHRP-2, GHRP-6, or hexarelin). The idea isn't invented by forum culture, even though forum culture is where most people first hear about it. Growth hormone release in the body is genuinely controlled by two separate signals converging on the same pituitary somatotroph cells: growth hormone releasing hormone (GHRH), which tells the cell to make and release GH, and ghrelin, acting through the growth hormone secretagogue receptor (GHS-R), which amplifies that release and also suppresses somatostatin, the hormone that normally puts the brakes on GH secretion [1]. CJC-1295 is a synthetic analogue of GHRH. Ipamorelin and the GHRPs are ghrelin receptor agonists. Combine one of each and you're hitting both arms of the natural axis instead of one. That's the entire scientific rationale for the stack, no more and no less. What it is not: a study-proven combination with measured outcomes in humans. Almost everything past the receptor biology is extrapolation, and a good deal of it is bodybuilding forum lore dressed up as physiology. Worth being honest about that distinction up front, because most of what's written about this stack online doesn't make it.
Why is CJC-1295 usually paired with ipamorelin specifically?
Ipamorelin is the most common partner because it is a selective ghrelin receptor agonist that, in the original pharmacology papers, released GH without meaningfully triggering ACTH, cortisol, or prolactin release, the side effects that plagued older GHRPs like GHRP-6 [2]. That selectivity is the whole pitch: less hormonal noise, at least in the mechanistic studies that first characterized it. Practically, that means people using ipamorelin generally report less of the appetite spike (a strong ghrelin-receptor effect) and less water retention or cortisol-driven irritability than with GHRP-6. Whether that translates into a meaningfully better outcome when combined with CJC-1295 in real users, over months, has not been tested in a controlled trial. The selectivity data comes from receptor-binding and animal/in-vitro pharmacology, not from a head-to-head human study of the stack. CJC-1295 without DAC (also sold as Mod GRF 1-29) has a short half-life, on the order of 30 minutes, so it produces a pulse of GH release that mimics the body's natural pulsatile pattern reasonably well [3]. Pairing a short-acting GHRH analogue with a short-acting ghrelin agonist like ipamorelin, dosed together once or twice a day, keeps the pulse pattern intact. That's the theoretical appeal over, say, combining ipamorelin with CJC-1295 with DAC, which sits in circulation for days and produces a flatter, less pulsatile elevation. For a full walkthrough of ipamorelin's own mechanism and dosing, see cjc 1295, which covers the base compound in depth.
CJC-1295 with DAC vs without DAC: does it change how you'd stack it?
| Half-life | ~30 minutes [3] | ~6-8 days [4] | |
|---|---|---|---|
| GH release pattern | Sharp, pulsatile | Sustained, flatter elevation | |
| Typical stacking approach | Paired same-session with ipamorelin/GHRP for a coordinated pulse | Dosed separately (often 1-2x/week); ghrelin agonist added daily on top | |
| Rationale for pairing with a GHS | Mimics natural dual-signal GH pulse | Keeps baseline GH/IGF-1 elevated while still allowing pulsatile spikes from the GHS | With DAC in the stack, most protocols described in practitioner and community sources still add a daily ghrelin agonist (ipamorelin most often) on the days between DAC injections, on the logic that the ghrelin signal still needs to happen for a real GH pulse, since DAC alone raises baseline GH/IGF-1 tone but doesn't itself trigger the same acute pulse that ghrelin agonists do. That layering strategy has not been studied directly either; it's inference built on two separate pharmacology datasets, not a combined-agent trial. See cjc 1295 with dac for the full mechanism and half-life discussion, and cjc-1295 dac dosage calculator if you're trying to work out injection frequency for the DAC version specifically. |
Yes, and this is the single most important distinction in the whole topic, more important than which GHRP you pick. CJC-1295 without DAC has a half-life of roughly 30 minutes in circulation [3]. It's cleared fast, so dosing is built around creating a clean GH pulse, typically once daily or before workouts, timed to pair with a ghrelin agonist for a coordinated spike. CJC-1295 with DAC (Drug Affinity Complex) is chemically modified to bind reversibly to albumin in the blood, extending its half-life to roughly 6 to 8 days based on the original pharmacokinetic study in healthy subjects, which found the modified peptide maintained significantly elevated GH and IGF-1 levels for multiple days after a single injection [4]. That study, published in the Journal of Clinical Endocrinology & Metabolism, is the actual primary source people are (usually unknowingly) citing when they say CJC-1295 with DAC 'lasts a week.' That pharmacokinetic difference changes how stacking logic applies: | Feature | CJC-1295 (no DAC) | CJC-1295 with DAC |
What does the actual clinical evidence show for CJC-1295 plus a GHRP or ipamorelin?
Essentially nothing, if the bar is a published human trial testing that exact combination for fat loss, muscle gain, recovery, or longevity outcomes. That needs to be said plainly because it is the single most misrepresented fact in this space. What does exist: the original Phase 1/2 trials of CJC-1295 with DAC, later summarized in the JCEM pharmacokinetic paper, tested the GHRH analogue alone, not combined with a ghrelin agonist [4]. Ipamorelin's foundational pharmacology (receptor selectivity, lack of ACTH/cortisol co-release) comes from earlier in-vitro and animal studies from the 1990s, again testing ipamorelin alone [2]. The combined mechanism, GHRH agonist plus ghrelin agonist producing synergistic GH release, does have supporting evidence, but it comes from studies using other GHRH analogues and other GHRPs, not from CJC-1295 and ipamorelin specifically. Classic endocrinology research from the 1990s established that GHRH plus a GHRP produces a greater acute GH pulse than either alone in humans [1], which is the actual scientific basis people are gesturing at when they claim the stack is synergistic. It's real physiology. It's just not a trial of the specific commercial products people are injecting today. Neither CJC-1295 nor ipamorelin is FDA-approved for any indication. Both are sold as "research chemicals" or through compounding pharmacies under varying degrees of regulatory scrutiny, and FDA's own bulk drug substance nomination process has evaluated GH secretagogue peptides for compounding eligibility, a process that speaks directly to how unsettled the regulatory footing is for this whole category [5]. That regulatory status matters more to stacking decisions than most articles admit: there is no standardized, quality-controlled combination product on the market. Anyone stacking these is combining two individually sourced peptides, at self-selected doses, with no clinical trial ever having verified the combination is safe or effective at any particular ratio.
How do people typically dose CJC-1295 when stacking it with ipamorelin?
Commonly described protocols, sourced from compounding pharmacy patient materials and peptide community writing rather than clinical trials, use CJC-1295 without DAC at roughly 100 mcg paired with ipamorelin at roughly 100-300 mcg, injected together subcutaneously, once or twice daily, often timed before bed and/or before training on an empty stomach [3]. With the DAC version, injection frequency drops to twice weekly or weekly given the multi-day half-life, sometimes still layered with daily ipamorelin. Those numbers are not doses established by a dose-ranging clinical trial for this stacked use case. They are numbers that have become customary through repetition across suppliers and forums. The original CJC-1295 DAC pharmacokinetic study used doses in the range of 30 to 60 mcg/kg body weight tested for GH/IGF-1 response in normal volunteers [4], which is a very different framework than the flat mcg doses circulating in community protocols. For the full breakdown of dosing conventions, injection timing, and how the DAC and non-DAC schedules differ in practice, see cjc 1295 dosage.
Is CJC-1295 stacked with anything besides ipamorelin?
Yes. The three combinations that show up most often in practitioner and community material are CJC-1295 with ipamorelin, CJC-1295 with GHRP-2, and CJC-1295 with GHRP-6. Less commonly, people add hexarelin or, further outside the GH-axis conversation entirely, unrelated peptides like BPC-157 for tissue repair claims that have nothing to do with GH secretion. GHRP-6 was one of the earliest ghrelin mimetics studied and does reliably raise GH, but it also has a stronger appetite-stimulating effect and, unlike ipamorelin, tends to raise cortisol and prolactin somewhat in the original comparative pharmacology work [2]. That's a real tradeoff: GHRP-6 may produce a bigger acute hunger response (some people want that for bulking; most don't) and carries more of the side-effect profile ipamorelin was specifically designed to avoid. GHRP-2 sits in between, generally considered to have a milder cortisol/prolactin effect than GHRP-6 but still more than ipamorelin in most comparative descriptions. None of these three-way or four-way stacks (CJC-1295 plus two different GHRPs, for instance) have any published trial data behind them at all. Adding a second ghrelin agonist on top of one you're already using doesn't add a new mechanism, since they compete for the same receptor. That's a case where more peptides is very likely just more cost and more injection burden without a plausible added GH benefit.
What are the safety considerations when combining CJC-1295 with a ghrelin agonist?
Combining two GH secretagogues raises the size of the acute GH and downstream IGF-1 elevation compared to either alone, based on the general endocrine principle that GHRH and ghrelin signals are additive [1]. Practically, that means side effects tied to elevated GH and IGF-1, water retention, joint achiness, and, over a longer horizon, glucose/insulin sensitivity changes, are plausible on the stack even if never formally measured in a trial of this pairing. CJC-1295 with DAC's long half-life is the specific safety wrinkle worth understanding: if a bad reaction or an incorrectly compounded batch causes a problem, you can't simply stop and clear it in a day, since it is still active in the body up to about a week later [4]. That is a meaningfully different risk profile than the non-DAC version, and it's a big reason the DAC and non-DAC choice deserves more attention than most buyers give it. Because neither peptide is FDA-approved and supply chain quality varies widely across compounding sources and "research chemical" vendors, contamination, mislabeled concentration, and simple dosing error are realistic risks independent of the peptide's own pharmacology [5]. Stacking two sourced-separately products compounds that sourcing risk rather than reducing it. For the fuller rundown of documented and theoretical side effects, see cjc 1295 side effects.
Does stacking actually work better than CJC-1295 alone?
Nobody has good data on this for the specific commercial combination people are using; the closest real evidence is the older clinical literature showing that combined GHRH-agonist-plus-GHRP dosing produces a larger acute GH pulse than either class alone in controlled human testing [1]. That's a real, replicated finding in endocrinology, not folklore. What's missing is any trial connecting that larger acute GH/IGF-1 pulse, produced specifically by CJC-1295 and ipamorelin together, to a meaningful downstream outcome like more muscle mass, more fat loss, better sleep, or slower aging over weeks or months of use. The acute hormone spike is measurable and real. What it adds up to over time, in this specific combination, at the doses people actually use, is unproven. Anyone telling you the stack is "definitely more effective" is speaking from the older single-agent literature and applying it by analogy to two named commercial peptides that have never been tested together in that literature. That's a reasonable inference. It is not the same as a demonstrated clinical outcome, and a careful reader should hold that distinction.
How do you actually get CJC-1295 and ipamorelin if you decide to try this?
Compounding pharmacies are the legal route most commonly used in the US, operating under state pharmacy board oversight and, for larger-scale compounders, FDA's 503B outsourcing facility framework, though CJC-1295 and related GH secretagogue peptides have faced ongoing FDA scrutiny over their compounding eligibility as bulk drug substances [5]. That regulatory picture shifts periodically, so anyone sourcing these should check current FDA guidance rather than assume the status quo holds indefinitely. Going through a provider-reviewed pathway, where a clinician evaluates whether the peptide is appropriate and a licensed pharmacy fulfills the prescription, is the more defensible route compared to unregulated online "research chemical" vendors, where there is no independent verification of purity, concentration, or even the correct peptide being in the vial. CJC-1295 Co's own sourcing guidance points toward that provider-reviewed model rather than direct-to-consumer research chemical sales, with a licensed pharmacy partner handling fulfillment once a clinician has signed off. For a broader look at sourcing options, pricing ranges, and how to evaluate a vendor's legitimacy, see cjc 1295 for sale.
Frequently asked questions
Can you take CJC-1295 and ipamorelin at the same time?
Yes, and it's the most common way both are used. They're typically drawn into the same syringe or injected back to back, since they act on different receptors (GHRH receptor and ghrelin receptor) and are meant to produce a combined GH pulse. No trial has tested that exact simultaneous-injection protocol for downstream outcomes, though the receptor pharmacology behind the pairing is well established [1][2].
Is CJC-1295 with DAC better for stacking than without DAC?
Neither is objectively "better"; they suit different goals. No-DAC CJC-1295 (half-life ~30 minutes) pairs naturally with a same-session ghrelin agonist for a clean pulse. DAC CJC-1295 (half-life ~6-8 days per the JCEM pharmacokinetic study) [4] keeps baseline GH/IGF-1 elevated across the week, with many protocols still adding daily ipamorelin for the acute pulsatile component.
What's the difference between ipamorelin and GHRP-6 in a CJC-1295 stack?
Ipamorelin is a selective ghrelin receptor agonist that early pharmacology studies found did not meaningfully raise cortisol or prolactin, unlike GHRP-6, which does and also stimulates appetite more strongly [2]. Most people choose ipamorelin for a cleaner side-effect profile; GHRP-6 users are usually chasing the appetite effect specifically.
Do you need to cycle CJC-1295 and ipamorelin, or take them continuously?
There's no clinical trial establishing an optimal cycle length for this stack. Community protocols commonly describe running it for 8 to 12 weeks with breaks, on the general endocrine logic that sustained receptor stimulation can lead to some downregulation over time, but that's an inference from broader hormone-receptor biology, not a study of this specific combination.
Does CJC-1295 stacked with ipamorelin help with fat loss?
GH and IGF-1 elevation, which this stack is designed to produce, are linked to increased lipolysis in classic endocrinology research generally. But no published trial has measured fat loss outcomes from CJC-1295 combined with ipamorelin specifically, so any fat-loss claim about the stack is extrapolated, not demonstrated.
Can you stack CJC-1295 with BPC-157?
People do, but the rationale is different from the CJC-1295/ipamorelin pairing since BPC-157 is marketed around tissue repair rather than GH-axis signaling and works through unrelated proposed mechanisms. There's no meaningful overlap in mechanism, and no combined trial data exists for that pairing either.
How much CJC-1295 and ipamorelin do people typically use together?
Community and compounding-pharmacy materials commonly describe roughly 100 mcg of no-DAC CJC-1295 with 100-300 mcg of ipamorelin, injected together once or twice daily [3]. These are customary doses, not doses established by a controlled dose-ranging trial for the combined product.
Is it legal to buy CJC-1295 and ipamorelin in the US?
Neither peptide is FDA-approved as a drug, and both have faced FDA review over eligibility for pharmacy compounding as bulk substances [5]. They exist in a regulatory gray zone: sourcing through a licensed compounding pharmacy under clinician oversight is the more defensible legal route compared to unregulated "research chemical" sellers.
What are the side effects of stacking CJC-1295 with a GHRP?
Expect the additive version of each compound's individual effects: water retention, joint achiness, injection site reactions, and with less-selective GHRPs like GHRP-6, appetite spikes and some cortisol/prolactin elevation [2]. Because the combination raises acute GH/IGF-1 more than either alone, side effects tied to that elevation are plausible even without formal trial data on the stack.
Does stacking increase the risk of side effects compared to CJC-1295 alone?
Almost certainly yes in magnitude, since GHRH and ghrelin signals are additive and the combination is designed to produce a bigger GH pulse than either compound alone [1]. Nobody has directly measured comparative side-effect rates between the stack and CJC-1295 alone, but the underlying mechanism supports a dose-response expectation.
How long does it take to see results from CJC-1295 and ipamorelin combined?
No trial has measured a results timeline for this specific stack. Community reporting commonly describes subjective sleep and recovery changes within 2 to 4 weeks and body composition changes, if any, over 8 to 12 weeks, but these are self-reported patterns, not measured trial endpoints.
Should you get CJC-1295 and ipamorelin from the same source?
Sourcing both from a single provider-reviewed pathway, where a clinician evaluates appropriateness and a licensed compounding pharmacy fulfills both prescriptions, reduces the number of unverified supply chains you're relying on. Buying each separately from different unregulated online vendors doubles your exposure to contamination or mislabeling risk.
Sources
- Bowers CY, "Growth hormone-releasing peptide (GHRP)", Cell and Molecular Life Sciences, PubMed: GHRH and ghrelin/GHRP signals act on separate pathways converging on the pituitary and produce additive GH release when combined
- Raun K et al., "Ipamorelin, the first selective growth hormone secretagogue", European Journal of Endocrinology, 1998: Ipamorelin is a selective GH secretagogue with minimal ACTH/cortisol co-release compared to other GHRPs
- National Center for Biotechnology Information, PubChem CID 71715350 (CJC-1295 no DAC): CJC-1295 without DAC has a short circulating half-life supporting pulsatile GH release
- Teichman SL et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting growth hormone-releasing hormone analog", Journal of Clinical Endocrinology & Metabolism, 2006, PMID 16352683: CJC-1295 with DAC has a half-life of approximately 6-8 days and sustains elevated GH and IGF-1 after a single dose
- U.S. Food and Drug Administration, 503A Bulks List Nominations Under Evaluation: CJC-1295 and related GH secretagogue peptides have been reviewed by FDA for compounding eligibility as bulk drug substances
- Corpas E, Harman SM, Blackman MR, "Human growth hormone and human aging", Endocrine Reviews, 1993, PMID 8325248: GHRH stimulation of the pituitary and the downstream GH/IGF-1 axis is well established in the endocrinology literature that underlies CJC-1295's mechanism